関連する実験動画
Updated: May 5, 2026

06:21
Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
9.7K
血液学的悪性腫瘍およびその影響要因を有する患者の症状負担
Yuying Zhang1, Wei Zhang1, Weiguang Ma2
1School of Nursing, Chinese Academy of Medical Sciences & Peking Union Medical College, Badachu Road #33, Beijing, 100144, China.
まとめ
血液学的悪性腫瘍の患者は,身体的な症状の重荷を大きく経験し,しばしば過小評価された心理的苦痛を経験します. 介入は,正確な症状評価と,高リスクの個人の早期スクリーニングに重点を置くべきである.
科学分野:
- 血液学 ヘマトロジ
- 腫瘍学 腫瘍学
- 症状管理 症状管理
背景:
- 血液学的悪性腫瘍は,患者の健康に影響を与える複雑な症状の負担を示します.
- 身体的および心理的な症状の相互作用を理解することは,効果的なケアに不可欠です.
研究 の 目的:
- 血液学的悪性腫瘍の患者における全般的,身体的,および心理的な症状の負担を評価する.
- 症状負担に影響を与える要因を特定する.
主な方法:
- 血液学的悪性腫瘍を患った405人の患者の便利なサンプル採取.
- Memorial Symptom Assessment Scale,Cancer Coping Modes Questionnaire,およびソーシャルサポートレートスケールを使用しました.
- 統計的分析には,クルスカル・ワリス H テスト,マン・ウィトニー U テスト,スピアーマン相関,一般化された線形モデリングが含まれていた.
主要な成果:
- 身体的な症状の負担 (0.44) は,心理的な症状の負担 (0.28) を大幅に上回りました.
- エネルギー不足が最も多い症状 (58.52%) でした.
- 女性の性別,少数の治療セッション,特定の対処スタイル (辞退,幻想) は,より高い症状の負担を予測しました. 白血病,リンパ腫,骨髄膜症候群,多発性骨髄腫は保護効果を示した.
結論:
- 患者は重大な身体症状の負担に直面し,心理的苦痛は潜在的に過小評価されています.
- 心理的な症状負担の正確な評価システムが必要である.
- 早期発見と介入のために,標準化されたスクリーニングメカニズムが推奨されます.
関連する概念動画
Regulation of Hematopoietic Stem Cells
4.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.2K
Role of Hematopoietic Growth Factors
4.0K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
4.0K
Bone Marrow Sampling and Transplants
1.7K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
1.7K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
3.9K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.9K
Therapeutic Drug Monitoring: Affecting Factors
271
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
271
Chronic Kidney Disease II: Clinical Manifestations
760
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
760
